Elamipretide / Forzinity

What it is

Elamipretide is the active ingredient in Forzinity, which FDA granted accelerated approval in September 2025 as the first treatment for Barth syndrome. Barth syndrome is a rare, serious mitochondrial disease.

The approval matters. So does its boundary: the product, population, outcome, and accelerated-approval pathway cannot be replaced with a broader claim about feeling younger or having more energy.

What humans actually show

• Very small pivotal record: FDA’s Drug Trials Snapshot describes 12 participants with genetically confirmed Barth syndrome at one U.S. site. All were male, and all weighed at least 30 kg.
• Randomized portion: The initial randomized crossover portion did not show superiority to placebo on its primary six-minute-walk and fatigue endpoints.
• Approval evidence: FDA says the approval was based on increased knee-extensor muscle strength observed during a longer open-label period, not during the randomized portion.
• Accelerated approval: The pathway allows earlier approval while confirmatory clinical work continues.
• What it does not establish: The trial does not establish anti-aging, generalized fatigue improvement, athletic enhancement, or wellness benefits in people without Barth syndrome.

FDA and U.S. status

Forzinity is FDA-approved to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg. Approval belongs to that identified drug product and labeled use.

Calling elamipretide “FDA-approved” without the product and indication is incomplete. Using the approval to validate an unrelated product or a general mitochondrial claim is a larger product-and-population leap.

Risks and warning limits

FDA describes serious hypersensitivity risk and frequent injection-site reactions in the small trial record. Rare-disease approval does not create a general safety conclusion for other populations or unidentified products.

PepCurrent does not provide dosing, sourcing, switching, or personalized treatment advice.

Product identity and quality limits

In a December 2025 warning letter to Darmerica LLC, FDA described one firm- and listing-specific mismatch: the listing for “Elamipretide (SS-31) Acetate” (NDC 71052-907) named peptide B27PD as the active ingredient in its Structured Product Labeling. FDA cited the listing under its misbranding findings. This record does not establish that every product sold as elamipretide has the same defect, and an NDC listing is not FDA approval. It does demonstrate why a peptide name, listing, or seller claim cannot by itself authenticate product identity.

What would change this answer

• Confirmatory trial requirements and updates
• Changes to FDA labeling
• Evidence in the exact Barth syndrome population
• Marketing that converts a narrow rare-disease indication into a general anti-aging claim
• Firm-specific FDA enforcement and listing records that expose product-identity mismatches

Sources and records

• FDA accelerated-approval announcement, 2025
• FDA Drug Trials Snapshot: Forzinity
• FDA integrated review for Forzinity
• FDA warning letter to Darmerica LLC, December 8, 2025

Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.